Wednesday, April 15, 2009

BiPar Sciences Acquired By Sanofi-aventis

French biotech firm Sanofi-aventis said Wednesday that the firm has signed an agreement to acquire Brisbane, California-based BiPar Sciences. BiPar is a developer of cancer treatments. According to the firms, the deal is worth up to $500M, depending on milestone payments. Bipar is venture funded by Asset Management Company, Canaan Partners, Domain Associates, Lighthouse Capital Partners, Polytechnos, Quantum Technology Partners, and Vulcan Capital.